Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of YL201 versus topotecan in relapsed small cell lung cancer
CTR20244294Phase 3Active
- Sponsor
- MediLink Therapeutics
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of YL201 in small cell lung cancer (SCLC) (2 arms), sponsored by MediLink Therapeutics. Started Dec 2024; status: active.
02
Drugs
YL201
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20244294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244294.